ArticleBrain and behavior2025
Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein-IgG Associated Disease Compared to Multiple Sclerosis.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Frequent early cognitive impairment in both pediatric MS and MOGAD.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLittle is known about cognitive outcomes in people with myelin oligodendrocyte glycoprotein-IgG associated disease (pwMOGAD). While there are similarities between MOGAD and multiple sclerosis (MS), further evaluation is needed to establish the distinct cognitive trajectories for each disease.
methodsRetrospective review of subjective cognitive changes was performed for adult pwMOGAD. Subsets of pwMOGAD completed a cognitive screening measure and/or comprehensive neuropsychological testing. Their performance was compared to age, sex, and race matched people with MS (pwMS; 3:1 ratio).
resultsApproximately half (51.6%) of pwMOGAD (n = 63) endorsed cognitive dysfunction. On a cognitive screening measure (Processing Speed Test [PST]), performance did not statistically differ between pwMOGAD (n = 36; M = -0.06, SD = 1.36) and pwMS (n = 108; M = -0.04, SD = 1.30), t(62.35) = 0.18, p = 0.86. Of the pwMOGAD who completed neuropsychological testing (total n = 14), 57% demonstrated cognitive impairment on at least one test, and 36% demonstrated impairment on two or more tests. These rates did not differ from pwMS. In pwMOGAD, deficits were most common in processing speed (38.5%) and verbal fluency, spatial judgment, and immediate list recall (14.3% each). PwMOGAD performed better than pwMS on measures of visuomotor processing speed (β = -0.378, t = -2.68, p = 0.01) and cognitive flexibility (β = -0.33, t = -2.27, p = 0.03) after controlling for age, sex, race, education, and disease duration.
conclusionsSubjective cognitive complaints and objective cognitive deficits were common among pwMOGAD. Approximately one-third of pwMOGAD demonstrated clinically significant cognitive impairment (2+ tests impaired) and individual level deficits were most common on measures of processing speed, verbal fluency, spatial judgment, and word list recall.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.